TNGX | Ticker Profile - Titan Protect

TNGX

Tango Therapeutics, Inc.

Healthcare · Biotechnology · NGM

$20.22

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$2.8B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-12.36

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

-188.2%

How much profit the company keeps from each dollar of revenue

ROE

-38.4%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$30.00

+48% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 10 analysts covering this stock

About Tango Therapeutics, Inc.

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

https://www.tangotx.com

Country: United States Employees: 137 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

1.028

Excellent risk-adjusted returns

Kelly Fraction

0.0619

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.801

Acceptable balance between returns and drawdown risk

Annual Return

72.7%

Historical annualised return based on price data

Max Drawdown

-90.8%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.22

Moves slightly more than the broader market

52W High

$28.41

29% below the year high

52W Low

$1.93

948% above the year low

Avg Volume

3,371,475

Average daily shares traded — higher means easier to buy and sell

Short Ratio

9.9

Days it would take all short sellers to cover — higher means more crowded

Short % Float

22.3%

Very high short interest — potential squeeze candidate

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.83

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

8.38

Heavy leverage — higher financial risk if revenues decline

Current Ratio

27.38

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

26.51

Like current ratio but excludes inventory — stricter test

Gross Margin

-126.8%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-206.2%

Profit from core operations before interest and tax

Free Cash Flow

$-68,235,000

Negative — the business is spending more than it generates

Revenue (TTM)

$57M

Total revenue over the last 12 months

Net Income

$-107,232,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$55.00

Target Median

$30.00

Target Low

$21.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go